Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83


Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives.

Meyerson JR, Tran EE, Kuybeda O, Chen W, Dimitrov DS, Gorlani A, Verrips T, Lifson JD, Subramaniam S.

Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):513-8. doi: 10.1073/pnas.1214810110. Epub 2012 Dec 24.


Structural mechanism of trimeric HIV-1 envelope glycoprotein activation.

Tran EE, Borgnia MJ, Kuybeda O, Schauder DM, Bartesaghi A, Frank GA, Sapiro G, Milne JL, Subramaniam S.

PLoS Pathog. 2012;8(7):e1002797. doi: 10.1371/journal.ppat.1002797. Epub 2012 Jul 12.


Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures.

Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang YK, Depetris R, Marozsan AJ, Sanders RW, Klasse PJ, Milne JL, Wilson IA, Olson WC, Moore JP, Subramaniam S.

Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11440-5. doi: 10.1073/pnas.1101414108. Epub 2011 Jun 27.


Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography.

White TA, Bartesaghi A, Borgnia MJ, de la Cruz MJ, Nandwani R, Hoxie JA, Bess JW, Lifson JD, Milne JL, Subramaniam S.

J Virol. 2011 Dec;85(23):12114-23. doi: 10.1128/JVI.05297-11. Epub 2011 Sep 21.


Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure.

White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, Bess JW, Nandwani R, Hoxie JA, Lifson JD, Milne JL, Subramaniam S.

PLoS Pathog. 2010 Dec 23;6(12):e1001249. doi: 10.1371/journal.ppat.1001249.


Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.

Dutta M, Liu J, Roux KH, Taylor KA.

J Virol. 2014 Nov;88(21):12265-75. doi: 10.1128/JVI.01596-14. Epub 2014 Aug 13.


Molecular architecture of native HIV-1 gp120 trimers.

Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S.

Nature. 2008 Sep 4;455(7209):109-13. doi: 10.1038/nature07159. Epub 2008 Jul 30.


Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.

Ingale J, Tran K, Kong L, Dey B, McKee K, Schief W, Kwong PD, Mascola JR, Wyatt RT.

J Virol. 2014 Dec;88(24):14002-16. doi: 10.1128/JVI.02614-14. Epub 2014 Sep 24. Erratum in: J Virol. 2015 Jun;89(12):6526.


PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.

Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker LM, Wu X, Seaman MS, Wrin T, Kwong PD, Wyatt RT, Mascola JR, Poignard P, Burton DR.

J Virol. 2012 Apr;86(8):4394-403. doi: 10.1128/JVI.06973-11. Epub 2012 Feb 15.


Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans.

Agrawal-Gamse C, Luallen RJ, Liu B, Fu H, Lee FH, Geng Y, Doms RW.

J Virol. 2011 Jan;85(1):470-80. doi: 10.1128/JVI.01349-10. Epub 2010 Oct 20.


Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env.

Scharf L, Wang H, Gao H, Chen S, McDowall AW, Bjorkman PJ.

Cell. 2015 Sep 10;162(6):1379-90. doi: 10.1016/j.cell.2015.08.035.


Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.

Feng Y, McKee K, Tran K, O'Dell S, Schmidt SD, Phogat A, Forsell MN, Karlsson Hedestam GB, Mascola JR, Wyatt RT.

J Biol Chem. 2012 Feb 17;287(8):5673-86. doi: 10.1074/jbc.M111.317776. Epub 2011 Dec 13.


HIV-1 envelope glycoprotein trimers display open quaternary conformation when bound to the gp41 membrane-proximal external-region-directed broadly neutralizing antibody Z13e1.

Harris AK, Bartesaghi A, Milne JL, Subramaniam S.

J Virol. 2013 Jun;87(12):7191-6. doi: 10.1128/JVI.03284-12. Epub 2013 Apr 17.


Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.

Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Ledgerwood JE, Graham BS, Haynes BF, Burton DR, Wyatt RT, Mascola JR.

J Virol. 2011 Sep;85(17):8954-67. doi: 10.1128/JVI.00754-11. Epub 2011 Jun 29.


Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates.

Douagi I, Forsell MN, Sundling C, O'Dell S, Feng Y, Dosenovic P, Li Y, Seder R, Loré K, Mascola JR, Wyatt RT, Karlsson Hedestam GB.

J Virol. 2010 Feb;84(4):1683-95. doi: 10.1128/JVI.01896-09. Epub 2009 Dec 2.


Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy.

Murin CD, Julien JP, Sok D, Stanfield RL, Khayat R, Cupo A, Moore JP, Burton DR, Wilson IA, Ward AB.

J Virol. 2014 Sep 1;88(17):10177-88. doi: 10.1128/JVI.01229-14. Epub 2014 Jun 25.


Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy.

Bartesaghi A, Merk A, Borgnia MJ, Milne JL, Subramaniam S.

Nat Struct Mol Biol. 2013 Dec;20(12):1352-7. doi: 10.1038/nsmb.2711. Epub 2013 Oct 23.


Fusion proteins of HIV-1 envelope glycoprotein gp120 with CD4-induced antibodies showed enhanced binding to CD4 and CD4 binding site antibodies.

Chen W, Feng Y, Wang Y, Zhu Z, Dimitrov DS.

Biochem Biophys Res Commun. 2012 Sep 7;425(4):931-7. doi: 10.1016/j.bbrc.2012.08.013. Epub 2012 Aug 11.


Unraveling the structural basis of HIV-1 neutralization.

Wright ER, Spearman PW.

Future Microbiol. 2012 Nov;7(11):1251-4. doi: 10.2217/fmb.12.104.


Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.

Sharma VA, Kan E, Sun Y, Lian Y, Cisto J, Frasca V, Hilt S, Stamatatos L, Donnelly JJ, Ulmer JB, Barnett SW, Srivastava IK.

Virology. 2006 Aug 15;352(1):131-44. doi: 10.1016/j.virol.2006.04.030.

Supplemental Content

Support Center